Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

被引:1
|
作者
Skoeld, Camilla [1 ]
Corvigno, Sara [2 ]
Dahlstrand, Hanna [2 ]
Enblad, Gunilla [1 ]
Mezheyeuski, Artur [3 ]
Sundstroem-Poromaa, Inger [4 ]
Stalberg, Karin [4 ]
Tolf, Anna [1 ]
Glimelius, Ingrid [1 ,5 ]
Koliadi, Anthoula [1 ]
机构
[1] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
[2] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[3] Vall dHebron Inst Oncol, Barcelona, Spain
[4] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden
[5] Karolinska Inst, Dept Med, Div Clin Epidemiol, Stockholm, Sweden
关键词
Ovarian cancer; Parity; Progesterone receptor; Tissue micro array; HORMONE-RECEPTOR EXPRESSION; RISK-FACTORS; PROGESTERONE; ESTROGEN; EPITHELIUM; APOPTOSIS; OVULATION; SURVIVAL;
D O I
10.1007/s10552-024-01876-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose High-grade serous ovarian cancer (HGSC) is the most common ovarian cancer subtype. Parity is an important risk-reducing factor, but the underlying mechanism behind the protective effect is unclear. Our aim was to study if the expression of hormones and proteins involved in pregnancy were affected by the woman's parity status, and if they may be associated with tumor stage and survival.Methods We evaluated expression of progesterone receptor (PR), progesterone receptor membrane component 1 (PGRMC1), relaxin-2, and transforming growth factor beta 1 (TGF beta 1) in tumor tissue from 92 women with HGSC parous (n = 73) and nulliparous (n = 19). Key findings were then evaluated in an independent expansion cohort of 49 patients. Survival rates by hormone/protein expression were illustrated using the Kaplan-Meier method. The independent prognostic value was tested by Cox regression, using models adjusted for established poor-prognostic factors (age at diagnosis, FIGO stage, type of surgery, and macroscopic residual tumor after surgery).Results HGSC tumors from parous women were PR positive (>= 1% PR expression in tumor cells) more often than tumors from nulliparous women (42% vs. 16%; p-value 0.04), and having more children was associated with developing PR positive tumors [i.e., >= 3 children versus nulliparity, adjusted for age at diagnosis and stage: OR 4.31 (95% CI 1.12-19.69)]. A similar result was seen in the expansion cohort. Parity status had no impact on expression of PGRMC1, relaxin-2 and TGF beta 1. No associations were seen with tumor stage or survival.Conclusion Tumors from parous women with HGSC expressed PR more often than tumors from nulliparous women, indicating that pregnancies might possibly have a long-lasting impact on ovarian cancer development.
引用
收藏
页码:1101 / 1109
页数:9
相关论文
共 50 条
  • [41] T-cell activation is associated with high-grade serous ovarian cancer survival
    Wang, Lei
    Sun, Wenjie
    Zhang, Guoan
    Huo, Jingrui
    Tian, Yi
    Zhang, Yan
    Yang, Xiaohui
    Liu, Yingfu
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2022, 48 (08) : 2189 - 2197
  • [42] VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer
    Liju Zong
    Yuncan Zhou
    Ming Zhang
    Jie Chen
    Yang Xiang
    Cancer Immunology, Immunotherapy, 2020, 69 : 33 - 42
  • [43] Identification of candidate genes associated with tubal origin of high-grade serous ovarian cancer
    Xiang, Li
    Rong, Guohua
    Zhao, Jing
    Wang, Zhenyan
    Shi, Fengfeng
    ONCOLOGY LETTERS, 2018, 15 (05) : 7769 - 7775
  • [44] VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer
    Zong, Liju
    Zhou, Yuncan
    Zhang, Ming
    Chen, Jie
    Xiang, Yang
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (01) : 33 - 42
  • [45] Nuclear SYK phosphorylation is associated with poor survival in high-grade serous ovarian cancer
    Yu, Y.
    Suryo, Y.
    Davidson, B.
    Africano, A. A.
    Fader, A. N.
    Wang, T. L.
    Shih, I. M.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 129 - 129
  • [46] The peritoneal tumour microenvironment of high-grade serous ovarian cancer
    Leinster, D. Andrew
    Kulbe, Hagen
    Everitt, Gemma
    Thompson, Richard
    Perretti, Mauro
    Gavins, Felicity N. E.
    Cooper, Dianne
    Gould, David
    Ennis, Darren P.
    Lockley, Michelle
    McNeish, Iain A.
    Nourshargh, Sussan
    Balkwill, Frances R.
    JOURNAL OF PATHOLOGY, 2012, 227 (02): : 136 - 145
  • [47] Centrosomes - The Achilles' heel of high-grade serous ovarian cancer?
    Chandrasekaran, G.
    Hall, D.
    Vias, M.
    Brenton, J. D.
    Gergely, F.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26
  • [48] Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months
    Rizzo, Stefania
    Botta, Francesca
    Raimondi, Sara
    Origgi, Daniela
    Buscarino, Valentina
    Colarieti, Anna
    Tomao, Federica
    Aletti, Giovanni
    Zanagnolo, Vanna
    Del Grande, Maria
    Colombo, Nicoletta
    Bellomi, Massimo
    EUROPEAN RADIOLOGY, 2018, 28 (11) : 4849 - 4859
  • [49] Determinants of resistance and response in high-grade serous ovarian cancer
    Bowtell, David D. L.
    CLINICAL CANCER RESEARCH, 2016, 22
  • [50] Characterization of candidate factors associated with the metastasis and progression of high-grade serous ovarian cancer
    Liu Huiping
    Zhou Ling
    Cheng Hongyan
    Wang Shang
    Luan Wenqing
    Cai E
    Ye Xue
    Zhu Honglan
    Cui Heng
    Li Yi
    Chang Xiaohong
    中华医学杂志英文版, 2023, 136 (24)